Saturday 17 October 2026
Export XBIO’s income statement to Excel — free account
Xenetic Biosciences, Inc.
XBIO Healthcare Biotechnology
Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.98
0.03
−1.49%
Follow XBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.69 | 1.24 | 1.92 | 2.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.36) | (15.21) | (11.45) | (7.63) | |
P/B ratio |
1.22 | 0.50 | 0.88 | 1.10 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.65 | (1.03) | (0.02) | 0.41 | |
EV/EBITDA |
0.00 | 1.08 | 0.03 | 0.00 | |
EV/Operating CF |
(0.68) | 1.34 | 0.04 | (0.58) | |
EV/FCF |
(0.68) | 1.34 | 0.04 | (0.58) | |
Quick Ratio |
3.71 | 8.14 | 7.67 | 7.23 | |
Current Ratio |
4.56 | 8.32 | 7.93 | 7.43 | |
Net Debt/EBITDA |
7.57 | 12.65 | 14.63 | 6.66 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.44 | 0.39 | 0.47 | 0.53 | |
Operating CF/Net income |
1.29 | 0.42 | 1.18 | 0.94 | |
Research and Development Expense of Revenue |
73.66% | 100.93% | 81.97% | 83.56% | |
Selling, General and Administrative Expense of Revenue |
79.38% | 80.37% | 80.26% | 163.53% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.55% | 1.83% | 1.40% | 7.87% | |
Graham Net Nets |
0.82 | 1.92 | 1.08 | 0.86 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(65.29%) | (73.27%) | (44.78%) | (39.86%) | |
Free Cash Flow Yield |
(56.09%) | (61.87%) | (29.63%) | (34.61%) | |
Revenue per Share |
0.67 | 0.45 | 0.35 | 0.29 | |
Operating CF per Share |
(0.43) | (0.14) | (0.23) | (0.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.43) | (0.14) | (0.23) | (0.38) | |
Cash per Share |
2.67 | 4.63 | 3.21 | 2.82 | |
Shareholders Equity per Share |
2.57 | 4.35 | 3.03 | 2.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.57 | 4.35 | 3.03 | 2.65 | |
Free Cash Flow |
(0.66) | (0.24) | (0.54) | (0.88) | |
Working Capital |
3.96 | 7.08 | 6.64 | 5.76 | |
Net Current Asset Value |
3.96 | 7.08 | 6.64 | 5.76 | |
EV/EBIT |
0.00 | 1.08 | 0.03 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.41 | 0.27 | 0.40 | 0.33 | |
Average Assets |
6.56 | 7.63 | 6.85 | 6.16 | |
Average Common Equity |
5.49 | 6.70 | 6.04 | 5.26 |
Columns are period end dates